Arcutis Biotherapeutics, Inc.ARQTReports Wed, Nov 4 · Third Quarter 2026
Key ratios
FCF / Sales
8.4%TTM
2025
-1.7%2024
-57.1%2023
-415.2%
Net margin
6.2%TTM
2025
-4.3%2024
-71.3%
ROA
5.1%TTM
2025
-2.0%2024
-23.3%2023
-38.1%
ROE
15.9%TTM
2025
-9.3%2024
-113.8%2023
-175.8%
Revenue growth
76.1%TTM
2025
91.3%2024
229.7%2023
1517.1%
Recent news
Arcutis Appoints Rob Scott, MD to Board of Directors
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
Track ARQT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer